Anesthetics to Prevent Lung Injury in Cardiac Surgery (APLICS): A protocol for a randomized, controlled trial

CURRENT STATUS: ACCEPTED

Brian P. O’Gara
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
ORCiD: 0000-0002-3868-7499

Balachundhar Subramaniam
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Shahzad Shaefi
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Ariel Mueller
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Valerie Banner-Goodspeed
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Daniel Talmor
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

DOI: 10.21203/rs.2.28/v2

SUBJECT AREAS
General Medicine

KEYWORDS
Inflammatory lung injury, volatile anesthetics, cardiac surgery, postoperative pulmonary complications, TNFa
Abstract

Background

Patients undergoing cardiac surgery with cardiopulmonary bypass are at an increased risk of developing postoperative pulmonary complications, potentially leading to excess morbidity and mortality. It is likely that pulmonary ischemia-reperfusion (IR) injury during cardiopulmonary bypass is a major contributor to perioperative lung injury. Therefore, interventions that can minimize IR injury would be valuable in reducing the excess burden of this potentially preventable disease process. Volatile anesthetics including sevoflurane have been shown in both preclinical and human trials to effectively limit pulmonary inflammation in a number of settings including ischemia-reperfusion injury. However, this finding has not yet been demonstrated in the cardiac surgery population. The Anesthetics to Prevent Lung Injury in Cardiac Surgery (APLICS) trial is a randomized, controlled trial investigating whether sevoflurane anesthetic maintenance can modulate pulmonary inflammation occurring during cardiac surgery with cardiopulmonary bypass, and whether this potential effect can translate to a reduction in postoperative pulmonary complications.

Methods

APLICS is a prospective, randomized controlled trial of adult cardiac surgical patients. Subjects will be randomized to receive intraoperative anesthetic maintenance with either sevoflurane or propofol. Patients in both groups will be ventilated according to protocols intended to minimize the influences of ventilator induced lung injury and hyperoxia. Bronchoalveolar lavage (BAL) and blood sampling will take place after anesthetic induction and between two to four hours after pulmonary reperfusion. The primary outcome is a difference between groups in the degree of post-bypass lung inflammation, defined by BAL concentrations of TNFα. Secondary outcomes will include differences in
additional relevant BAL and systemic inflammatory markers and the incidence of postoperative pulmonary complications.

Discussion

APLICS investigates whether anesthetic choice can influence lung inflammation and pulmonary outcomes following cardiac surgery with cardiopulmonary bypass. A positive result from this trial would add to the growing body of evidence describing the lung protective properties of the volatile anesthetics and potentially reduce unnecessary morbidity for cardiac surgery patients.

Trial Registration

ClinicalTrials.gov identifier NCT02918877, registered on September 29, 2016.

Background

Patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) are at an increased risk for postoperative pulmonary complications (PPCs), with recent estimates of the incidence as high as 50% (1, 2). Overt respiratory failure and acute respiratory distress syndrome (ARDS) can occur in as many as 10% of patients, leading to mortality rates up to forty times higher than patients without these conditions (3). Pulmonary ischemia-reperfusion (IR) injury during cardiopulmonary bypass (CPB) has been identified as a major contributor to perioperative lung injury, but to date strategies to mitigate such injury have failed to demonstrate a consistent benefit (4, 5). Volatile anesthetics have been shown to protect the lung from various etiologies of inflammatory lung injury in both preclinical models and in humans (6-9). Proposed mechanisms for this observed effect include a reduction in the release of inflammatory mediators from pulmonary neutrophils and macrophages, and preservation of alveolar endothelial integrity (10). Although the volatile anesthetic sevoflurane has been shown to prevent myocardial injury from IR after cardiac surgery, there has been a lack of data showing whether its use in this population
can result in a similar level of protection from IR lung injury (11). Given the excess morbidity and mortality associated with PPCs in this population, investigation into whether the use of volatile anesthetics such as sevoflurane can reduce lung injury after CPB could impact the outcomes of thousands of cardiac surgical patients a year (12).

Methods And Design

Study Design

The Anesthetics to Prevent Lung Injury in Cardiac Surgery (APLICS) trial is a randomized, controlled, single center clinical trial of adult cardiac surgical patients undergoing CPB. Subjects are randomized to receive intraoperative anesthetic maintenance with either sevoflurane or propofol. Mechanical ventilation is standardized in both groups in order to limit potential confounding from ventilator induced lung injury and hyperoxia. In addition, anesthetic providers are asked to avoid the administration of additional modulators of lung injury including nitrous oxide, steroids, and cisatracurium. Lung inflammation will be evaluated by analyzing differences in the pre- and post-bypass pulmonary TNF between groups, obtained via a bronchoalveolar lavage (BAL). Secondary outcomes include differences in other key pulmonary and systemic inflammatory biomarkers, as well as the incidence of PPCs. A study schema is provided in Figure 1. Comment by Brian O’Gara: Response to reviewer 2 comment 1 (M&D) Comment by Brian O’Gara: Added for clarity and consistency

Setting

This study is being conducted at Beth Israel Deaconess Medical Center (BIDMC) in Boston. BIDMC is a 700-bed tertiary care hospital academically affiliated with Harvard Medical School. More than 900 open-heart procedures with CPB are performed at BIDMC each year.

Study Registration

Institutional Review Board (IRB) approval was obtained from the Committee on Clinical
Investigations at BIDMC (IRB Protocol 2016P000306). APLICS was registered on clinicaltrials.gov with the identifier NCT02918877. Upon completion of the trial, results will be reported according to the Consolidated Standards of Reporting Trials (CONSORT) guidelines and the Standard Protocols Items: Recommendations for Interventional Trials (Figure 2, Figure 3). The trial is active and ongoing, and any amendments made to the protocol are reported to and approved by the BIDMC IRB prior to implementation.

**Inclusion and Exclusion Criteria**

Patients are deemed eligible for enrollment if they are greater than or equal to 18 years of age and are scheduled to undergo cardiac surgery with CPB. Patients undergoing off-pump procedures (not requiring CPB) are not included, as this study aims to evaluate the role of anesthetic type following subsequent IR lung injury following CPB. Patients are excluded if they are having emergency surgery, have a history of severe chronic obstructive or restrictive lung disease (as evident by spirometry), recent (within two weeks) use of systemic glucocorticoids, prior history of pneumothorax, allergy or contraindication to propofol, or have a personal, family history, or are at increased risk of malignant hyperthermia.

**Randomization**

After informed consent performed by study MD’s, participants are allocated in a 1:1 fashion using block randomization to receive intraoperative anesthetic maintenance using either sevoflurane or propofol. The REDCap randomization module hosted at BIDMC is used in order to implement the study randomization schema by study personnel before any study interventions take place (13).

**Intervention Group: Anesthetic Maintenance with Sevoflurane**

Patients in the sevoflurane arm receive anesthetic maintenance (between anesthetic induction and the completion of surgery, including while on CPB) with 0.7-1.5 minimum
alveolar concentration (MAC) sevoflurane. As clinical conditions may dictate dosing outside of these ranges, for instance in the event of extreme variations in blood pressure, anesthesiologists are asked to maintain an average MAC dose per hour within the specified range.

*Comparison Group: Anesthetic Maintenance with Propofol*

Patients randomized to the propofol arm receive anesthetic maintenance with intravenous propofol at a suggested dosing range of 50-200mcg/kg/min. Anesthesiologists are given preference as to the specific dose required to achieve a satisfactory plane of anesthesia and hemodynamic stability, as well as whether to administer additional agents typically included during a total intravenous anesthetic (e.g. remifentany) or to use bispectral index monitoring.

*Intraoperative Clinical Management in Both Groups*

Anesthetic providers for patients in both groups are asked to avoid the administration of additional potential modulators of lung injury including nitrous oxide, steroids, and cisatracurium.

As mechanical ventilation can potentially induce confounding inflammatory lung injury and the administration of a high fraction of inspired oxygen (FiO2) can potentially worsen pulmonary IR injury, we have standardized the mechanical ventilation and oxygenation of the study patients according to the following guidelines:

- Tidal volume will be set at 6 to 8cc/kg of ideal body weight.
- Positive end expiratory pressure will be set between 2 and 12 cmH2O.
- FiO2 will be equal to or less than 50% and titrated to target peripheral oxygen saturation greater than 92%. Brief exposures (<20 minutes) to a FiO2 of 100% for hypoxia or during the immediate post-CPB period are allowed.
- Peak airway pressure goal of less than 40 cmH2O.
· Plateau pressure goal of than 35 cm H2O.
· Arterial partial pressure of carbon dioxide (PaCO2) will be maintained between 20 and 60 mmHg.
· Arterial partial pressure of oxygen (PaO2) will be maintained between 60 and 200 mmHg.

Protocol adherence will be facilitated by real time conversations between the study team and the anesthesiologist, and post hoc quantification of adherence will be performed by review of the anesthetic record. Comment by Brian O'Gara: Added to improve readability

*Drop Out Criteria*

The anesthesia team has the discretion to terminate the study protocol at any time in the interest of patient safety. This would include decisions made by the anesthesiologist to deliver a different anesthetic or to administer a steroid, for example in the event of suspected anaphylaxis. In addition, study subjects will not be included in the analysis of the primary outcome if the patient is deemed at high risk for complications during a study bronchoscopy, and BAL samples cannot be obtained. This includes instances of severe hypoxia (defined as a PaO2/FiO2 ratio of less than 100 or oxygen saturation [SpO2] less than 90%), positive end expiratory pressure values greater than 15 cmH20, or patients with fraction of inspired oxygen (FiO2) greater than 80% in order to maintain a SpO2 greater than 90%. Finally, the study intervention can be terminated at any time due to significant nursing or treating physician concern.

*Blinding*

This is an unblinded trial. The primary outcome of the study relies on the measurement of laboratory values which are not influenced by provider bias. Furthermore, effective blinding of the anesthesia team or the study group members to randomization assignment would require the use of both a lipid emulsion placebo to mimic the administration of propofol and a sham vaporizer to mimic the administration of sevoflurane. Additionally,
study members who assess secondary outcomes are limited to the identification of PPCs via chart review as documented by the treating clinical team, laboratory values, and radiographic data as interpreted by independent radiologists uninformed of study participation or group assignment. Comment by Brian O'Gara: Changed from Furthermore, to improve readability Comment by Brian O'Gara: Response to reviewer 2, comment 7 (M&D)

Study Procedures: Sample Collection Comment by Brian O'Gara: Response to reviewer 2, comment 8 (M&D)

BAL and serum collection take place at two clearly defined time points. The first sample collection occurs after anesthetic induction with endotracheal intubation and before surgical incision. The second sample collection takes place between two and four hours after removal of the aortic cross clamp. This window was chosen as it historically has been described as the time when the peak pulmonary inflammatory response occurs after reperfusion (4). All BAL samples are obtained by a member of the study team with the appropriate training according to current BIDMC policy and procedure for BAL collection. Direct vision bronchoscopy is utilized for this purpose to minimize the risk of trauma from unintentional misplacement of a catheter. A flexible bronchoscope is passed through the endotracheal tube and gently wedged into the right lower lobe bronchus. A total of 60cc of a sterile saline solution, typically in 30cc instillations, is then used to lavage the cavity. Continuous suction is then used to obtain the residual lavage specimen (usually 10 to 20cc) for laboratory analysis of the markers indicated below. Serum collection consists of one 10cc ethylenediaminetetraacetic acid (EDTA) tube per time point and is obtained via catheters placed as part of the usual care for cardiac surgery.

Specimen Processing

Blood and BAL specimens are centrifuged at 25°C at 2,300 x g for 10 minutes. The plasma
and buffy coat are separated from red blood cells, aliquoted into smaller cryovials, labeled and frozen at -80°C for subsequent batch analysis. The BAL specimen is also aliquoted, labeled and frozen in a similar fashion. All specimens are labeled with a unique coded ID and will not contain any patient identifiers.

Data Collection

Clinical and demographic variables are collected and reported including age, body mass index, Society of Thoracic Surgeons (STS) predicted mortality score and comorbidities (e.g. history of myocardial infarction, congestive heart failure, diabetes, dyslipidemia, hypertension, stroke, peripheral vascular disease, and smoking). All patient data is stored anonymously in a REDCap database hosted at BIDMC. REDCap is a secure, web-based application designed to support data capture for clinical trials that allows customized data collection fields to support individual trial needs. Members of the research team are responsible for building and maintaining the electronic case report form, as well as monitoring data entry for completeness, timeliness and accuracy. During the informed consent process, subjects are asked separately to consent to specimen storage for use in future studies.

Primary Outcome: Incidence of Inflammatory Lung Injury

The degree of inflammatory lung injury will be assessed by comparing the levels of key inflammatory mediators and biomarkers of lung injury found in patient BAL fluid and serum before and after exposure to cardiopulmonary bypass. Although to date there has not been a clear consensus on the ideal biomarker of pulmonary injury, we have chosen TNF as our primary outcome to be consistent with the findings of studies done in thoracic surgery where the exposure to pulmonary IR injury is similar to cardiac surgery (8). In addition to TNF, the indicators tested for as secondary outcomes in this study will likely include interleukin (IL) 1b/6/8, monocyte chemoattractant protein (MCP) 1, total protein,
neutrophil count, soluble receptor for advanced glycosylation end products (sRAGE), angiopoietin 1 and 2, surfactant protein D, and soluble intercellular adhesion molecule 1 (ICAM1). These indicators have been implicated as markers of lung inflammation and injury in previous studies (14). Our list of indicators will potentially be expanded as additional novel biomarkers that are currently unknown but available at the time of analysis are identified. Comment by Brian O'Gara: Response to reviewer 2, comment 9 (M&D)

Secondary Outcome: Incidence of Postoperative Pulmonary Complications

The incidence of pulmonary complications will be observed between both groups until discharge. PPCs are defined as a composite of: ARDS according to the Berlin Criteria, atelectasis, pleural effusion, pneumonia, pneumothorax, bronchospasm, exacerbation of chronic lung disease, reintubation, or ventilator dependence greater than 48 hours (15). This definition is in accordance with the recent consensus definition of PPCs reached by the ESA/ESICM taskforce and ARISCAT risk scoring system (16, 17). In addition, the incidence of hypoxia (PaO2/FiO2 < 300) and respiratory acidosis (partial pressure of carbon dioxide > 45 mmHg) will be included in a separate composite model, in light of the potential relation of hypoxia and hypercarbia to lung injury and the clinical consequences of these findings with regards to patient management.

Reporting of compliance and adverse events

A specialist within the research group will monitor protocol compliance, occurrence and reporting of adverse events to the IRB.

Sample Size & Power

A previous trial evaluating the effect of Sevoflurane versus Propofol during thoracic surgery found a 40% relative reduction in post-injury increase of alveolar TNF for the Sevoflurane group (8). Based on this effect size estimate, and assuming a two-sided $\alpha$ of
0.05 and 80% power, we estimate that 32 subjects would be required to detect a difference of more than 40% in alveolar TNF concentrations between groups. We aim to ultimately enroll a total of 20 subjects per group in order to assess potential differences in other inflammatory markers as secondary outcomes. Additional participants may be enrolled in order to ensure a total of 40 analyzable data sets are obtained after accounting for potential withdrawal of patients before randomization (e.g. surgery changes, patient withdrawal). Analysis of our secondary aims will likely be underpowered, but will be used to identify the incidence of PPCs and support future power calculations into the relationship between anesthetic use and PPCs. Comment by Brian O'Gara: Revised in response to Reviewer 1 comment

*Statistical Analysis*

We will use SAS software version 9.4 or later (SAS Institute, Cary, NC) to conduct all analyses. Descriptive statistics of the data will be assessed and presented as mean (± standard deviation), median (interquartile range), or frequencies and proportions depending on variable type and distribution. Normality will be assessed with the use of the Shapiro-Wilk test. Differences between groups in continuous variables will be compared using parametric or non-parametric t-tests as appropriate. Categorical data will be compared using a chi-square or Fishers Exact test for small cell counts. Two-sided p-values less than 0.05 will be considered statistically significant for all analyses.

*Analysis of the Primary Outcome*

Our primary outcome, differences in BAL TNF levels found before and after exposure to CPB, will be assessed using a paired t-test or Wilcoxon signed rank sum test as appropriate. A similar analysis will be performed for additional BAL and serum biomarkers as secondary outcomes. It is anticipated that randomization should account for potential differences between groups at baseline; however, more sophisticated adjustment, for
example with multivariable logistic regression, for potential confounders may occur if differences between groups persist after randomization in relevant categories such as surgery type and duration of aortic cross clamping. Comment by Brian O’Gara: Added for clarification

Analysis of Secondary Outcomes: PPCs Comment by Brian O’Gara: Added for clarification

In order to assess the relationship between anesthetic type and postoperative pulmonary complications, logistic regression will be used, with data presented as odds ratios and 95% confidence intervals. In the event that the outcome is more common than expected (> 10% incidence), we will employ the use of log-binomial regression, presenting relative risk estimates and their confidence intervals. Individual outcomes will also be reported in order to see if any early trends emerge between the sevoflurane and propofol groups. In addition, we plan to perform two subgroup analyses of postoperative pulmonary complications, one stratified by baseline risk and the other including the variables for hypoxia and hypercarbia variables. Risk will be calculated according to the ARISCAT preoperative pulmonary risk score and assessed using quartiles in order to reduce the potential for results to be skewed by the distribution of the data. Components of the ARISCAT scores will be calculated for each patient based off their ASA classification, functional status, and presence of preoperative sepsis. Similar regression analyses will then be used to ascertain differences between anesthetic groups and incidence of postoperative complications in each strata of risk.

Protocol Funding Sources and Their Role

This study is supported by the American Society of Anesthesiologists’ Foundation for Anesthesia Education and Research. Funds have been allotted from this organization to support principal investigator time and effort. The scientific content of the study protocol and execution of the trial is in no way influenced by this funding source. Protocol
development, execution and adherence, as well as scientific content development are supported under the Center for Anesthesia Research Excellence (CARE) within the Department of Anesthesia, Critical Care and Pain Medicine at BIDMC.

Discussion

The APLICS trial will be the first to evaluate the potential for anesthetic choice to reduce inflammatory lung injury after cardiac surgery. Given the high incidence of PPCs in this cohort, a reduction in inflammation could theoretically lead to an improvement in outcomes for an increasingly large group of at-risk patients. Recently, a similar trial conducted in lung cancer surgery patients demonstrated a significant reduction in PPC incidence from the use of sevoflurane as compared to propofol (18). The proposed mechanism for this finding was a decrease in pulmonary inflammation as evident by a reduction in the release of pulmonary pro-inflammatory cytokines in the sevoflurane group. A similar result from our trial would add to the growing body of evidence that the use of the inhaled anesthetics including sevoflurane for surgical anesthesia can lead to a reduction in pulmonary inflammation and potentially improved clinical outcomes.

Our study has several limitations. First, APLICS is not powered to detect a difference in clinical outcomes. The reasons for this design choice are multifactorial. Although the mechanism for lung injury in thoracic and cardiac surgery are similar, a reduction in lung inflammation with the use of the inhaled anesthetics as compared to propofol has not yet been demonstrated in this patient group. Therefore we thought it important to power a smaller study to detect a difference in chemical inflammatory mediators before conducting a larger clinical trial aimed at identifying potential differences in clinical outcomes. A second limitation of APLICS is the potential for bias that comes with the lack of assessor blinding. As discussed above, the requirements for the adequate intraoperative blinding of the clinical and study teams to the group assignment were thought to be excessive given
the objective nature of the primary outcome. A more relevant source of bias through lack of blinding can occur during the assessment of the secondary outcome, PPCs. Our group has taken several steps to reduce this potential source of bias. First, our definition of PPCs is consistent with international consensus. Second, the determination of PPCs is largely made through the interpretation of laboratory results and radiographic data obtained through the course of usual care and thus interpreted by clinical personnel unaware of the study and group assignment. In the cases where there is potential for a subjective assignment of PPCs, for example pneumonia, study staff are restricted to indentifying pneumonia only from chart review of diagnoses made by clinical staff who were unaffiliated with the trial.

Another limitation of our study is the potential for propofol exposure in the sevoflurane group. Clinicans are permitted to use any anesthetic induction agent of their choosing, including propofol. Since we hypothesize that the critical exposure period for the anesthetic-mediated prevention of IR lung injury is during CPB, this potential for contamination between groups was thought to be minimal in comparison to the safety benefit afforded to the clinical team in achieving a safe anesthetic induction in patients at high risk for hemodynamic compromise. Along the same lines, anesthesia and ICU providers were also allowed freedom of choice in deciding the safest and most effective means of postoperative sedation, including the use of propofol infusions. The scientific benefit of maintaining strict control of the study exposure is outweighed by a need to maximize patient safety.

The APLICS trial will be the first to evaluate whether the use of sevoflurane as compared to propofol for anesthetic maintenance can reduce the degree of inflammatory lung injury following exposure to cardiopulmonary bypass. A positive result from APLICS would add to a growing body of evidence supporting the potential lung protective effects of the volatile
anesthetics. If such a finding could potentially lead to a reduction in patient morbidity by limiting PPCs, it could mean that the simple intervention of anesthetic choice could impact the successful recovery of thousands of cardiac surgical patients per year.

List Of Abbreviations

APLICS: Anesthesia to Prevent Lung Injury in Cardiac Surgery

BAL: Bronchoalveolar lavage

TNF: Tumor necrosis factor alpha

CPB: Cardiopulmonary bypass

PPCs: Postoperative pulmonary complications

ARDS: Acute Respiratory Distress Syndrome

SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials

BIDMC: Beth Israel Deaconess Medical Center

IRB: Institutional Review Board

CONSORT: Consolidated Standards of Reporting Trials

MAC: Minimum alveolar concentration

Mcg: Microgram

Kg: Kilogram

Min: Minute

FiO2: Fraction of Inspired Oxygen

cc: Cubic Centimeter

cm: Centimeter

H2O: Water

PaCO2: Arterial partial pressure of carbon dioxide

PaO2: Arterial partial pressure of oxygen

SpO2: Peripheral oxygen saturation
STS: Society of Thoracic Surgeons
REDCap: Research Electronic Data Capture
IL: Interleukin
MCP: Monocyte chemoattractant protein
sRAGE: Soluble receptor for advanced glycosylation end-products
ICAM: Intercellular adhesion molecule
ESA: European Society of Anaesthesiology
ESICM: European Society of Intensive Care Medicine
ARISCAT: Assess Respiratory Risk in Surgical Patients in Catalonia
CARE: Center for Anesthesia Research Excellence
ICU: Intensive Care Unit

Declarations

Trial Status
The trial is ongoing and currently recruiting. Recruitment began in 05/2016 and is expected to be completed in 03/2019. The most recent protocol version is 2016P000306/14 (dated 08/27/18) and was approved by the BIDMC IRB on 10/15/2018.

Ethics Approval and Consent to Participate
This study has been approved by the Committee on Clinical Investigations at Beth Israel Deaconess Medical Center (IRB Protocol # 2016P000306). Written informed consent will be obtained from all study participants.

Consent for Publication
Not applicable.

Availability of Data and Material
Data from the current study is available from the corresponding author upon reasonable request.
Competing Interests

The authors declare that they have no competing interests.

Funding

This study is supported by the Foundation for Anesthesia Education and Research (Mentored Training Research Grant). Funds have been allotted from this organization to support principal investigator time and effort. Protocol development, execution and adherence, as well as scientific content development are supported by the Center for Anesthesia Research Excellence (CARE) within the BIDMC Department of Anesthesia, Critical Care and Pain Medicine.

Dr. O’Gara is funded by a Foundation of Anesthesia Education and Research (FAER) Mentored Research Training Grant. Dr. Talmor is funded by grants from the NIH/NHLBI and from the Department of Defense/US Army.

Authors’ Contributions

All authors have contributed to the conception or design, acquisition, analysis, or interpretation of data or manuscript preparations for this study. BO is the principal investigator and conceived of the idea for this trial along with the senior investigators BS and DT. BO, SS, AM, VBG, BS and DT drafted, reviewed and finalized the study protocol.

BO and AM developed the statistical analysis plan. BO, BS, SS, AM, VBG and DT have been involved in drafting and critically revising the manuscript. All authors have read and approved the final version of this manuscript.

Acknowledgements

The authors would like to acknowledge the contributions from the staff of the BIDMC Center for Research Excellence who assisted greatly in regulatory compliance, data collection, and assessment of secondary outcomes. In addition, the authors would like to thank the members of the BIDMC Cardiac Anesthesia Division. Without their efforts, this
study would not have been possible.

Author's Information

1Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA 02215, USA

References

1. Canet J, Gallart L, Gomar C, Paluzie G, Valles J, Castillo J, et al. Prediction of postoperative pulmonary complications in a population-based surgical cohort. Anesthesiology. 2010;113(6):1338-50.

2. Cueva LF, Bausili M, González R, Ardila C, Galán J. Postoperative pulmonary complications in cardiac surgery patients: a prospective cohort, single-centre study: 5AP2-8. European Journal of Anaesthesiology (EJA). 2014;31:80.

3. Milot J, Perron J, Lacasse Y, Letourneau L, Cartier PC, Maltais F. Incidence and predictors of ARDS after cardiac surgery. Chest. 2001;119(3):884-8.

4. Hall RI, Smith MS, Rocker G. The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations. Anesthesia and analgesia. 1997;85(4):766-82.

5. Apostolakis EE, Koletsis EN, Baikoussis NG, Siminelakis SN, Papadopoulos GS. Strategies to prevent intraoperative lung injury during cardiopulmonary bypass. Journal of cardiothoracic surgery. 2010;5:1.

6. Ferrando C, Aguilar G, Piqueras L, Soro M, Moreno J, Belda FJ. Sevoflurane, but not propofol, reduces the lung inflammatory response and improves oxygenation in an acute respiratory distress syndrome model: a randomised laboratory study. European journal of anaesthesiology. 2013;30(8):455-63.

7. De Conno E, Steurer MP, Wittlinger M, Zalunardo MP, Weder W, Schneiter D, et al. Anesthetic-induced improvement of the inflammatory response to one-lung ventilation.
8. Schilling T, Kozian A, Senturk M, Huth C, Reinhold A, Hedenstierna G, et al. Effects of volatile and intravenous anesthesia on the alveolar and systemic inflammatory response in thoracic surgical patients. Anesthesiology. 2011;115(1):65-74.

9. Strosing KM, Faller S, Gyllenram V, Engelstaedter H, Buerkle H, Spassov S, et al. Inhaled Anesthetics Exert Different Protective Properties in a Mouse Model of Ventilator-Induced Lung Injury. Anesthesia and analgesia. 2016.

10. O’Gara B, Talmor D. Lung protective properties of the volatile anesthetics. Intensive care medicine. 2016;42(9):1487-9.

11. Li F, Yuan Y. Meta-analysis of the cardioprotective effect of sevoflurane versus propofol during cardiac surgery. BMC Anesthesiol. 2015;15:128.

12. Shander A, Fleisher LA, Barie PS, Bigatello LM, Sladen RN, Watson CB. Clinical and economic burden of postoperative pulmonary complications: patient safety summit on definition, risk-reducing interventions, and preventive strategies. Critical care medicine. 2011;39(9):2163-72.

13. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. Journal of biomedical informatics. 2009;42(2):377-81.

14. Ware LB, Calfee CS. Biomarkers of ARDS: what’s new? Intensive care medicine. 2016;42(5):797-9.

15. Force TADT. Acute respiratory distress syndrome: The berlin definition. Jama. 2012;307(23):2526-33.

16. Jammer I, Wickboldt N, Sander M, Smith A, Schultz MJ, Pelosi P, et al. Standards for definitions and use of outcome measures for clinical effectiveness research in
perioperative medicine: European Perioperative Clinical Outcome (EPCO) definitions: a statement from the ESA-ESICM joint taskforce on perioperative outcome measures. European journal of anaesthesiology. 2015;32(2):88-105.

17. Canet J, Gallart L. Predicting postoperative pulmonary complications in the general population. Current opinion in anaesthesiology. 2013;26(2):107-15.

18. de la Gala F, Pineiro P, Reyes A, Vara E, Olmedilla L, Cruz P, et al. Postoperative pulmonary complications, pulmonary and systemic inflammatory responses after lung resection surgery with prolonged one-lung ventilation. Randomized controlled trial comparing intravenous and inhalational anaesthesia. British journal of anaesthesia. 2017;119(4):655-63.

Figures

Figure 1

TIVA – Total Intravenous Anesthesia (Propofol) IA – Inhaled Anesthetic (Sevoflurane) ICU – Intensive Care Unit
| TIMEPOINT** | STUDY PERIOD | ENROLMENT & ALLOCATION | POST-ALLOCATION |
| --- | --- | --- | --- |
| | Prior to Surgery | Day of Surgery | Postoperatively Daily During the Hospital Stay |
| TIMEPOINT** | Enrolment & Allocation | Post-allocation |
| **STUDY PERIOD** | | | |
| Enrolment & Allocation | | | |
| Post-allocation | | | |
| **Day of Surgery** | | | |
| Pre Bypass | | | |
| 2-4 Hours After Aortic Clamp Removed | | | |
| Postoperatively Daily During the Hospital Stay | | | |
| **ENROLLMENT:** | | | |
| Eligibility Screen | X | | |
| Informed Consent | X | | |
| Group Allocation | X | | |
| **INTERVENTIONS** | | | |
| Inhaled Anesthetic (Sevoflurane) | | X* | |
| Total Intravenous Anesthesia (Propofol) | | X* | |
| **ASSESSMENTS** | | | |
| Bronchoalveolar Lavage (BAL) | | X | X |
| Blood Collection | X | X | |
| Assess Intraoperative Protocol Adherence | | X* | |
| Assess Postoperative Pulmonary Complications (PPCs) | | X | |

*Administered or assessed between anesthetic induction and the completion of surgery, including while on cardiopulmonary bypass.

Figure 2
SPirit Figure

Supplementary Files
This is a list of supplementary files associated with the primary manuscript. Click to download.

Figure 3 APLICS SPIRIT checklist.doc
WHO Registration Data Set - APLICS.docx
EQUATOR checklist explanation.docx